Hyperactive Ras as a therapeutic target in neurofibromatosis type 1

被引:1
|
作者
Weiss, B
Bollag, G
Shannon, K
机构
[1] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[2] Onyx Pharmaceut, Small Mol Therapeut, Richmond, CA USA
来源
AMERICAN JOURNAL OF MEDICAL GENETICS | 1999年 / 89卷 / 01期
关键词
neurofibromatosis type 1; experimental therapeutics; Ras;
D O I
10.1002/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The NF1 gene encodes neurofibromin, a GTPase-activating protein (GAP) for members of the p21(ras) (Ras) family, which negatively regulates Ras output by accelerating the conversion of active Ras GTP to inactive Ras-GDP. Analysis of tumors from patients with neurofibromatosis type 1 (NF1) has shown biochemical evidence of hyperactive Ras as well as frequent loss of the normal NF1 allele, consistent with its role as a tumor suppressor gene. Taken together, these data suggest that novel therapeutics directed against components of the Ras signaling cascade might provide effective treatments for certain pathological complications of NF1. Here we summarize data that support a role for hyperactive Ras in NF1 disease, including Ras processing, activation,and down-regulation. We review targets for rational drug design, provide preliminary results, and discuss implications for future studies. Am. J. Med. Genet. (Semin. Med. Genet.) 89:14-22, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:14 / 22
页数:9
相关论文
共 50 条
  • [1] HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1
    Omrani, A.
    van der Vaart, T.
    Mientjes, E.
    van Woerden, G. M.
    Hojjati, M. R.
    Li, K. W.
    Gutmann, D. H.
    Levelt, C. N.
    Smit, A. B.
    Silva, A. J.
    Kushner, S. A.
    Elgersma, Y.
    [J]. MOLECULAR PSYCHIATRY, 2015, 20 (11) : 1311 - 1321
  • [2] HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1
    A Omrani
    T van der Vaart
    E Mientjes
    G M van Woerden
    M R Hojjati
    K W Li
    D H Gutmann
    C N Levelt
    A B Smit
    A J Silva
    S A Kushner
    Y Elgersma
    [J]. Molecular Psychiatry, 2015, 20 : 1311 - 1321
  • [3] Emerging therapeutic targets for neurofibromatosis type 1
    Walker, James A.
    Upadhyaya, Meena
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (05) : 419 - 437
  • [4] RAS and beyond: the many faces of the neurofibromatosis type 1 protein
    Anastasaki, Corina
    Orozco, Paola
    Gutmann, David H.
    [J]. DISEASE MODELS & MECHANISMS, 2022, 15 (02)
  • [5] MINIPIG MODELS OF NEUROFIBROMATOSIS TYPE 1 FOR THERAPEUTIC DEVELOPMENT
    Watson, Adrienne
    Osum, Sara
    Taisto, Mandy
    Tschida, Barbara
    Duerre, Dylan
    Moertel, Christopher
    Kirstein, Mark
    Largaespada, David
    Oribamise, Eunice
    [J]. NEURO-ONCOLOGY, 2020, 22 : 88 - 88
  • [6] Neurofibromatosis type 1: Its association with the Ras/MAPK pathway syndromes
    Bennett, Emma
    Thomas, Nick
    Upadhyaya, Meena
    [J]. JOURNAL OF PEDIATRIC NEUROLOGY, 2009, 7 (02) : 105 - 115
  • [7] The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1
    Barkan, Batya
    Starinsky, Sigal
    Friedman, Eitan
    Stein, Reuven
    Kloog, Yoel
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5533 - 5542
  • [8] Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers
    Sealover, Nancy E.
    Finniff, Bridget
    Hughes, Jacob
    Lee, Hyun
    Kortum, Robert L.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [9] Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers
    Sealover, Nancy
    Finniff, Bridget
    Kortum, Robert
    [J]. MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [10] Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB
    Guilding, Clare
    McNair, Kara
    Stone, Trevor W.
    Morris, Brian J.
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2007, 25 (01) : 99 - 105